I'm giving the variant update at the SAVE meeting on Monday so I thought I'd put out a preview for comment.
We are now at our 4th 'high water' mark since the Omicron wave based on wastewater surveillance.
1/
I thought I would give an abbreviated summary of the last year in variants.
A little over a year ago BA.2.86 started circulating, a lineage that was almost certainly derived from a persistent infection. 2/
BA.2.86 was pretty fit, but it was still sensitive to a lot of Class 1 antibodies.
However, it quickly picked up S:L455S (making it JN.1), which evaded these antibodies, and it was off to the races. 3/
JN.1 played around with a lot of mutations, but its favorite was F456L, a change that it independently picked up at least 20 times. 4/
We then started seeing lineages that combined 456L with the old favorite R346T, which was the same change that BA.4/5 picked up during the summer 2 years ago.
This happened lots of times, but the best know was probably KP.2. 5/
But those lineages got some competition when another 456L lineage picked up R493E (KP.3).
For whatever reason this really only happened once. I'm not sure why. It was a C->G mutation, which is rare.
KP.3 seemed to be fitter than the 456L/346T gang. 6/
I always expected KP.3 to pick up R346T, but there hasn't appeared to be much selective pressure for that to happen. There's probably some redundancy in 346T/493E advantages.
7/
Then the 346T/456L group found a neat trick. They deleted position S31, which gave them the leg up again.
8/
But of course, KP.3 figured out that it could do that too.
The S31 deletion has occurred lots of times now, but the fittest among them seems to be KP.3.1.1. 9/
So what does the S31 deletion do. It's been reported to both increase fitness (higher infectivity in pseudotype assays), and antibody evasion.
The deletion introduces a glycosylation site, but it also restores the insertions/deletion balance in that part of Spike. 10/
RaTG-13 had a glycosylation site at this position too, and I've seen it introduced in lots of cryptic lineages.
However, I never saw the 31 deletion until the JN.1 insertion occurred. Probably because of the insertion/deletion balance thing.
11/
If I were smart I would put a 3D structure here showing why they insertion/deletion balance is important, but I'm not that smart (and it's just a theory).
12/
So what are we watching now?
There is a chimera-of-chimeras in China called XDV.1 that is doing pretty well there, but not really anywhere else.
Its spike is derived from JN.1, but it doesn't have any of the 'advanced' changes.
It does have the XBB Orf9b:I5T though.
13/
Finally there is the new chimera that just got designated, XEC. This one just appeared in June and has fared pretty well. I don't think it could keep up with KP.3.1.1 currently, but if it picks up a few more changes it might.
14/
Overall it's an odd time. It's pretty clear that KP.3.1.1 (and equivalent) is going to have a sweep the world the way that JN.1 did, but I'm not sure what happens after that.
We'll be watching.
15/15
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We are recruiting sewersheds for an expanding project. Basically, we want to learn everything that can be learned from wastewater.
Read on if you are interested. 1/
This is a collaboration with SecureBio that started about 18 months.
Basically, we isolate the viral fraction from wastewater and sequence the crap out of it (~1 billion reads/sample). This is unbiased sequencing; we don’t want to miss anything. 2/ securebio.org
There are three main levels to the analysis of the wastewater virome.
The first is SecureBio’s main focus, which is novel pathogen detection with a particular focus on engineered pathogens. 3/ naobservatory.org/blog/detecting…
This battle between Harvard and the administration is so befuddling. The latest plot twist makes less sense than the last season of Lost.
Let me give a very quick summary for those not following along.
1/11
The last few weeks Harvard had been talking with the administration about concerns over antisemitism on campuses, but the talks lacked details, and Harvard was told that they would get a letter last Friday with more specifics.
2/
Then last Friday Harvard got an email from the acting general counsel of HHS with a scorched earth list of demands that would have effectively ended Harvard’s autonomy in hiring, admissions and curriculum.
Last month there was an announcement that I thought was a major advancement in world health, but it got little attention.
I thought I would tell you all a little bit about it and why it is so important.
1/25
This breakthrough has to do with HIV, which was a zoonotic pathogen. The progenitor of HIV infects chimpanzees in Cameroon.
No one knows exactly when or how HIV crossed into humans, but the first undisputed HIV patient sample (discovered retrospectively) was from 1959 in what is now the Democratic Republic of Congo.
HIV smoldered for decades before becoming widespread in the early 80s.
At the time, being diagnosed with an HIV infection was a death sentence.
There was no real cure (still isn’t) and no treatment. By any measure, HIV was one of the worst diseases of the last century. 3/ nature.com/articles/d4158…
I briefly thought the SA BA.3.2 was in the US, but it turns out the virus was just messing with me again.
This was kind of interesting though.
1/
We've been screening all of the new wastewater data a few times a week for signs of BA.3.2.
One of the many screens we have is looking for reads that have C21846T+T21864C together, which are in BA.3.2 but no current lineages (it works better to look for pairs of changes).
2/
This week we had a hit. This was the genotype of the read:
Here’s the problem we hope this dashboard will help solve. SARS-CoV-2 remains very prevalent in the US.
However, sequence surveillance from patients has plummeted. In addition to fewer samples, the average sequence takes >3 weeks to be reported (and it’s getting slower).
2/
Fortunately, we have wastewater surveillance (primarily through CDC NWSS), which covers a large chunk of the population and has a fairly fast turnaround (<2 weeks).